Antitubercular Agents

• 

  Subject Areas on Research

  • A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. 
  • A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania. 
  • A short history of dapsone, or an alternative model of drug development. 
  • ATS Core Curriculum 2014: part I. Adult pulmonary medicine. 
  • Advances in basic and translational tuberculosis research: Proceedings of the first meeting of RePORT international. 
  • Adventures within the speckled band: heterogeneity, angiogenesis, and balanced inflammation in the tuberculous granuloma. 
  • Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment. 
  • Alcohol use and clinical manifestations of tuberculosis. 
  • Antepartum or postpartum isoniazid treatment of latent tuberculosis infection. 
  • Are free anti-tuberculosis drugs enough? An empirical study from three cities in China. 
  • Are tuberculosis patients adherent to prescribed treatments in China? Results of a prospective cohort study. 
  • Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study. 
  • Central nervous system infection and cutaneous lymphadenitis due to Mycobacterium kansasii in an immunocompetent patient. 
  • Common Variants in the Glycerol Kinase Gene Reduce Tuberculosis Drug Efficacy. 
  • Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. 
  • Corticosteroids for tuberculous pericarditis: can we learn from variability? 
  • Cost-effectiveness of alternative strategies for interferon-γ release assays and tuberculin skin test in tuberculous uveitis. 
  • Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. 
  • Current issues in global tuberculosis control. 
  • Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. 
  • Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. 
  • Diagnostic and therapeutic challenges. 
  • Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial. 
  • Drug-resistant tuberculosis control in China: progress and challenges. 
  • Exogenous reinfection of tuberculosis in a low-burden area. 
  • Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. 
  • Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. 
  • Global tuberculosis control report. 
  • How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives. 
  • Impact of Community-Based DOT on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. 
  • Impact of an innovative tuberculosis financing and payment model on health service utilization by tuberculosis patients in China: do the poor fare better than the rich? 
  • Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. 
  • Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. 
  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. 
  • Isoniazid preventive therapy in medium-incidence settings: the price is right. 
  • Lack of consensus in the diagnosis and treatment for ocular tuberculosis among uveitis specialists. 
  • Long-term remission for disseminated Mycobacterium avium-intracellulare complex associated with antibody deficiency. 
  • Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. 
  • Medicine. A portfolio model of drug development for tuberculosis. 
  • Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements. 
  • Mitochondrial Impairment in Antibiotic Induced Toxic Optic Neuropathies. 
  • Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. 
  • Molecular Diagnostics for Mycobacterium tuberculosis Infection. 
  • Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. 
  • Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. 
  • Monitored isoniazid prophylaxis for low-risk tuberculin reactors. 
  • Mortality before or during treatment among tuberculosis patients in North Carolina, 1993-2003. 
  • Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. 
  • Mycobacteria: treatment approaches and mechanisms of resistance. 
  • Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. 
  • Over- and under-treatment of TB patients in Eastern China: an analysis based on health insurance claims data. 
  • Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. 
  • Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. 
  • Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. 
  • Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection. 
  • Pott's disease caused by Mycobacterium xenopi: case report and review. 
  • Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings. 
  • Rapid molecular detection of tuberculosis and rifampin resistance. 
  • Rate of resolution of histologically verified intracranial tuberculomas. 
  • Reply to Seddon, Schaaf, and Hesseling. 
  • Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. 
  • Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. 
  • Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. 
  • Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. 
  • Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. 
  • Successful cure of extensively drug-resistant pulmonary tuberculosis in a young child. 
  • Successful treatment of disseminated BCG in a patient with severe combined immunodeficiency. 
  • Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. 
  • The Effect of an Innovative Financing and Payment Model for Tuberculosis Patients on Health Service Utilization in China: Evidence from Hubei Province of China. 
  • The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population. 
  • The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. 
  • The race to eliminate tuberculosis. 
  • Three months of rifapentine and isoniazid for latent tuberculosis infection. 
  • Translating tuberculosis research into practice: collaboration between academic researchers and public health departments in North Carolina. 
  • Treating multidrug-resistant tuberculosis in community settings: a wise investment. 
  • Tuberculoma of the choroid. 
  • Tuberculosis patient expenditure on drugs and tests in subsidised, public services in China: a descriptive study. 
  • Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. 
  • Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. 
• 

  Keywords of People

  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology